Web site at: http://innovation.cms.gov/initiatives/index.html. Paper copies can be obtained by writing to Steven Johnson at the address listed in the ADDRESSES section of this notice.

II. Collection of Information Requirements

The information collection requirements associated with this notice are subject to the Paperwork Reduction Act of 1995; however, the information collection requirements are currently approved under the information collection request associated with OMB control number 0938–0880 entitled “Medicare Waiver Demonstration Applicant.” Applicants must submit the Medicare Waiver Demonstration Application to be considered for this program.

(Catalog of Federal Domestic Assistance Program No. 93.773, Medicare—Hospital Insurance; and Program No. 93.774, Medicare—Supplementary Medical Insurance Program)

Dated: August 20, 2013.

Marilyn Tavenner, Administrator, Centers for Medicare & Medicaid Services.

[FR Doc. 2014–02062 Filed 1–31–14; 4:15 pm]

BILLING CODE 4120–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA–2014–N–0053]

Designation of High-Risk Foods for Tracing; Request for Comments and for Scientific Data and Information

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice; request for comments and for scientific data and information.

SUMMARY: The Food and Drug Administration (“FDA” or “we”) is announcing the opening of a docket to obtain comments and scientific data and information that will help us to implement the section of the FDA Food Safety Modernization Act (FSMA) that requires FDA to designate high-risk foods. We are providing an opportunity for interested parties to submit comments and scientific data and information that will help us develop our process for implementing this provision.

DATES: Submit electronic or written comments and scientific data and information by April 7, 2014.

ADDRESSES: You may submit comments and scientific data and information, identified by Docket No. FDA–2014–N–0053, by any of the following methods:

Electronic Submissions
Submit electronic comments and scientific data and information in the following way:


Written Submissions
Submit written submissions in the following ways:

- Mail/Hand delivery/Courier (for paper submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

Instructions: All submissions received must include the Agency name and Docket No. FDA–2014–N–0053 for this notice. All comments and scientific data and information received may be posted without change to http://www.regulations.gov, including any personal information provided. For additional information on submitting comments and scientific data and information, see the “Comments” heading of the SUPPLEMENTARY INFORMATION section of this document.

Docket: For access to the docket to read background documents or comments and scientific data and information received, go to http://www.regulations.gov and insert the docket number found in brackets in the heading of this document into the “Search” box and follow the prompts and/or go to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm 1061, Rockville, MD 20852.


SUPPLEMENTARY INFORMATION:

I. Background

A. FDA Food Safety Modernization Act Proposal Requiring Designation of High-Risk Foods

On January 4, 2011, the President signed the FDA Food Safety Modernization Act (FSMA) (Pub. L. 111–353) into law. Section 204 of FSMA requires, among other things, the designation of high-risk foods. Specifically, section 204(d)(2)(A) of FSMA requires FDA to designate high-risk foods for which additional recordkeeping requirements are appropriate and necessary to protect the public health, and to do so not later than 1 year after the date of enactment of FSMA (and thereafter, if necessary). Section 204(d)(2)(B) requires FDA to publish the list of high-risk foods on the Internet Web site of FDA at the time when FDA issues final rules to establish the additional recordkeeping requirements for high-risk foods.

Section 204(d)(2)(A) of FSMA specifically states that the designation of high-risk foods must be based on the: (1) Known safety risks of a particular food, including the history and severity of foodborne illness outbreaks attributed to such food, taking into consideration foodborne illness data collected by the Centers for Disease Control and Prevention; (2) likelihood that a particular food has a high potential risk for microbiological or chemical contamination or would support the growth of pathogenic microorganisms due to the nature of the food or the processes used to produce such food; (3) point in the manufacturing process of the food where contamination is most likely to occur; (4) likelihood of contamination and steps taken during the manufacturing process to reduce the possibility of contamination; (5) likelihood that consuming a particular food will result in a foodborne illness due to contamination of the food; and (6) likely or known severity, including health and economic impacts, of a foodborne illness attributed to a particular food.

Through this notice, we are establishing a docket to provide an opportunity for interested parties to provide comments and scientific data and information that will help us refine our draft approach to identifying high-risk foods, as required by section 204(d)(2) of FSMA. Section 1.IB summarizes our tentative draft approach for the review and evaluation of data to designate high-risk foods. Attached as a reference to this notice is a draft approach document in which we describe the process and methodology we are considering using for designating high-risk foods. After reviewing comments received in response to this notice on the draft approach described here, we plan to further revise the approach as necessary. We also anticipate that the approach will be reviewed by scientific experts (“peer reviewed”).

While section 204(d)(2)(A) of FSMA includes a statutory deadline within 1 year of the enactment of FSMA, FDA is issuing this notice to solicit comments and scientific data and information that will help us refine our draft approach to identifying high-risk foods. In section II.B, there are a number of specific
topics on which we think various stakeholders and the public at large could provide valuable comments and scientific data and information to assist us in implementing section 204 of FSMA. We anticipate that this input will be critical to our effective implementation of section 204 of FSMA.

B. Draft Approach To Implement Section 204(d)(2) of FSMA—Designation of High-Risk Foods

Data and information developed to identify the most significant foodborne contaminants, including data and information regarding the number, severity, and related costs of illnesses, may be used as data inputs for the high-risk foods approach, where applicable and appropriate.

The draft approach would use a multicriteria decision analysis approach, similar to that of Anderson et al., 2011 (Ref. 1), to identify those foods which should be designated as high-risk. This approach would use the specific criteria identified in section 204(d)(2)(A) of FSMA and would implement those criteria within a risk model. For each of the food and hazard pairs identified, we would determine a total risk score by the weighted sum of the score for each of the defined criteria. For foods that have multiple risk scores because they appear in the list associated with more than one hazard, we would determine the total score for that food using each of the individual food-hazard pair total risk scores. Inclusion on the high-risk food list would be based on the total risk score for foods or food categories. We describe our draft approach, criteria, and scoring system, and provide examples, in the document entitled “FDA’s Draft Approach for Designating High-Risk Foods as Required by Section 204 of FSMA” (Ref. 2). Although the analysis would encompass food-hazard pairs, we do not anticipate this to be a food-hazard list but rather a food list. This draft approach may be further refined pending stakeholder input in response to this notice.

II. Request for Comments and Scientific Data and Information

We invite comments on the draft approach outlined in section 1.B and the submission of scientific data and information relevant to high-risk food designation. We anticipate that this general input, along with the more specific input we solicit below, will significantly assist the Agency in fulfilling the requirements of section 204 of FSMA. In particular, we invite comment, scientific data, and information on the following topics:

- Considering available data, uncertainty with the data, and the intended methods, what alternative approaches should we consider to identify high-risk foods?
- What additional criteria should we consider, within the bounds of the factors Congress mandated in section 204(d)(2)(A) of FSMA, to develop the list of high-risk foods? For example, in addition to the public health related economic impact of foodborne illnesses, which the draft approach takes into account, should the approach include nonpublic health economic impact factors, such as costs related to disruption in the food supply following a foodborne illness outbreak? If so, how should we determine these costs given the variety of foods and different market values for various foods?
- What changes should we consider making to the scoring system to ensure the range of possibilities for the foods and hazards is comprehensive and enhance the scoring?
- What changes should we consider making to the approach to better evaluate risk associated with animal food?
- The draft approach would equally weight the criteria. Should individual weights be assigned to each criterion? If so, which criteria should receive more weight and how should those weights be assigned?
- The draft approach would utilize the food categorization scheme used for the Reportable Food Registry (Ref. 3). What other practical alternatives to this food categorization scheme should we consider in light of the practical constraints of evaluating individual commodities?
- Adverse reactions may occur when allergic consumers are exposed to foods that contain undeclared allergens. Undeclared allergens may be present in a food through either mislabeling or cross-contact during processing and handling. Both situations present a risk to allergic consumers because they lead to incomplete or inaccurate product labels. How should food allergens, including the major food allergens defined in the Food Allergen Labeling and Consumer Protection Act of 2004 (Pub. L. 108–282, Title II) (milk, eggs, fish, Crustacean shellfish, tree nuts, peanuts, wheat, and soybeans), be considered in the development of the high-risk food list?

C. Additional Information and Data Requested

We also are interested in the following types of information and data:

- Scientific data and methods that can be used to assess the public health impact of acute or chronic exposures to pathogens and chemical contaminants in human food or animal food. In particular, scientific data and methods related to chronic exposures to chemical contaminants in food.
- For representative foods in each food category or commodity group to be evaluated:
  - A list of the pathogens and chemical contaminants likely to be found in the food;
  - The percentage prevalence of contaminants in the food;
  - The levels of contaminants in the food;
  - The point in the manufacturing process where the contaminants are likely to be introduced in the food; and
  - The typical steps and control measures taken in the manufacturing process to reduce the possibility of contamination of the food with the pathogen or chemical contaminant.

III. Comments

Interested persons may submit either electronic comments and scientific data and information regarding this document to http://www.regulations.gov or written comments to the Division of Dockets Management (see ADDRESSES). It is only necessary to send one set of comments and scientific data and information. Identify comments and scientific data and information with the docket number found in brackets in the heading of this document. Received comments and scientific data and information may be seen in the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday, and will be posted to the docket at http://www.regulations.gov.

IV. References

The following references have been placed on display in the Division of Dockets Management (see ADDRESSES) and may be seen by interested persons between 9 a.m. and 4 p.m., Monday through Friday, and are available electronically at http://www.regulations.gov. FDA has verified the Web site addresses in this reference section, but we are not responsible for any subsequent changes to the Web sites after this document publishes in the Federal Register.

IMPLEMENTATION: The technology will facilitate earlier specific diagnoses and lead to better antifungal therapy implementation for infected patients. Potential Commercial Applications:

- Directing antifungal drug therapy for improved patient outcomes
- Detection, discrimination of Candida species from biological samples
- Addressing secondary infections of immunosuppressed individuals

Competitive Advantages:

- Easily adapted for use in kits
- High-throughput capable
- Rapid and cost-effective

Development Stage: In vitro data available

Inventors: Christine J. Morrison, Errol Reiss, Brian Holloway, Jong Hee Shin


US Patent No. 6,242,178 issued 05 Jun 2001

Various international issued patents

Related Technologies:

- HHS Reference No. E–293–2013/0
- HHS Reference No. E–322–2013/0
- HHS Reference No. E–332–2013/0
- HHS Reference No. E–353–2013/0

Licensing Contact: Whitney Blair, J.D. M.P.H.; 301–435–4937; whiteney.blair@nih.gov

Nuclear Acid Assays for the Detection and Discrimination of Aspergillus Fungi Species within Biological Samples

Description of Technology: This invention relates to assays for the detection and species-specific identification of Aspergillus fungi. Accurate clinical diagnosis of Aspergillus species has become increasingly important as certain species, such as *A. terreus* and *A. fumigatus*, are resistant to specific commonly employed antifungal compounds. Most contemporary fungal diagnostic methods are time-consuming and inaccurate. This invention directly addresses those inadequacies by providing a method to rapidly and accurately differentiate all medically important species of Aspergillus based on differences in the DNA sequences of the internal transcribed spacer 1 region of ribosomal DNA.

Potential Commercial Applications:

- Directing antifungal drug therapy for improved patient outcomes
- Detection, discrimination of Aspergillus species from biological samples
- Addressing secondary infections of immunosuppressed individuals

Competitive Advantages:

- Easily adapted for use in kits
- High-throughput capable
- Rapid and cost-effective

Development Stage: In vitro data available

Inventors: Christine J. Morrison, Errol Reiss, Brian Holloway, Jong Hee Shin


US Patent No. 6,235,890 issued 22 May 2001

Various international issued patents